Literature DB >> 12411292

Primary immune responses to human CMV: a critical role for IFN-gamma-producing CD4+ T cells in protection against CMV disease.

Laila E Gamadia1, Ester B M Remmerswaal, Jan F Weel, Frederieke Bemelman, René A W van Lier, Ineke J M Ten Berge.   

Abstract

The correlates of protective immunity to disease-inducing viruses in humans remain to be elucidated. We determined the kinetics and characteristics of cytomegalovirus (CMV)-specific CD4(+) and CD8(+) T cells in the course of primary CMV infection in asymptomatic and symptomatic recipients of renal transplants. Specific CD8(+) cytotoxic T lymphocyte (CTL) and antibody responses developed regardless of clinical signs. CD45RA(-)CD27(+)CCR7(-) CTLs, although classified as immature effector cells in HIV infection, were the predominant CD8 effector population in the acute phase of protective immune reactions to CMV and were functionally competent. Whereas in asymptomatic individuals the CMV-specific CD4(+) T-cell response preceded CMV-specific CD8(+) T-cell responses, in symptomatic individuals the CMV-specific effector-memory CD4(+) T-cell response was delayed and only detectable after antiviral therapy. The appearance of disease symptoms in these patients suggests that functional CD8(+) T-cell and antibody responses are insufficient to control viral replication and that formation of effector-memory CD4(+) T cells is necessary for recovery of infection.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12411292     DOI: 10.1182/blood-2002-08-2502

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  144 in total

1.  Molecular profiling of cytomegalovirus-induced human CD8+ T cell differentiation.

Authors:  Kirsten M L Hertoghs; Perry D Moerland; Amber van Stijn; Ester B M Remmerswaal; Sila L Yong; Pablo J E J van de Berg; S Marieke van Ham; Frank Baas; Ineke J M ten Berge; René A W van Lier
Journal:  J Clin Invest       Date:  2010-11       Impact factor: 14.808

2.  Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant.

Authors:  Corinna La Rosa; Jeff Longmate; Simon F Lacey; Teodora Kaltcheva; Rahul Sharan; Denise Marsano; Peter Kwon; Jennifer Drake; Brenda Williams; Sharon Denison; Suenell Broyer; Larry Couture; Ryotaro Nakamura; Sanjeet Dadwal; Morris I Kelsey; Arthur M Krieg; Don J Diamond; John A Zaia
Journal:  J Infect Dis       Date:  2012-03-07       Impact factor: 5.226

Review 3.  Living in a house of cards: re-evaluating CD8+ T-cell immune correlates against HIV.

Authors:  George Makedonas; Michael R Betts
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

4.  B7-mediated costimulation of CD4 T cells constrains cytomegalovirus persistence.

Authors:  Ramon Arens; Andrea Loewendorf; Min J Her; Kirsten Schneider-Ohrum; Geoffrey R Shellam; Edith Janssen; Carl F Ware; Stephen P Schoenberger; Chris A Benedict
Journal:  J Virol       Date:  2010-10-27       Impact factor: 5.103

Review 5.  CD4 T-cell immunotherapy for chronic viral infections and cancer.

Authors:  Alice O Kamphorst; Rafi Ahmed
Journal:  Immunotherapy       Date:  2013-09       Impact factor: 4.196

6.  Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation.

Authors:  Katia Perruccio; Antonella Tosti; Emanuela Burchielli; Fabiana Topini; Loredana Ruggeri; Alessandra Carotti; Marusca Capanni; Elena Urbani; Antonella Mancusi; Franco Aversa; Massimo F Martelli; Luigina Romani; Andrea Velardi
Journal:  Blood       Date:  2005-08-25       Impact factor: 22.113

7.  In vitro priming and expansion of cytomegalovirus-specific Th1 and Tc1 T cells from naive cord blood lymphocytes.

Authors:  Kyung-Duk Park; Luciana Marti; Joanne Kurtzberg; Paul Szabolcs
Journal:  Blood       Date:  2006-05-04       Impact factor: 22.113

8.  Granzyme M targets host cell hnRNP K that is essential for human cytomegalovirus replication.

Authors:  R van Domselaar; S A H de Poot; E B M Remmerswaal; K W Lai; I J M ten Berge; N Bovenschen
Journal:  Cell Death Differ       Date:  2012-10-26       Impact factor: 15.828

9.  Restriction of Human Cytomegalovirus Infection by Galectin-9.

Authors:  Allison Abendroth; Brian P McSharry; Barry Slobedman; Emily A Machala; Selmir Avdic; Lauren Stern; Dirk M Zajonc; Chris A Benedict; Emily Blyth; David J Gottlieb
Journal:  J Virol       Date:  2019-01-17       Impact factor: 5.103

10.  Differential CMV-specific CD8+ effector T cell responses in the lung allograft predominate over the blood during human primary infection.

Authors:  Matthew R Pipeling; Erin E West; Christine M Osborne; Amanda B Whitlock; Lesia K Dropulic; Matthew H Willett; Michael Forman; Alexandra Valsamakis; Jonathan B Orens; David R Moller; Noah Lechtzin; Stephen A Migueles; Mark Connors; John F McDyer
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.